MGNX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

27.81M

+43.69%

-0.290

+15.84%

9.27M

-29.76%

-0.632

-2.73%

9.27M

-58.34%

-0.635

+11.36%

Estimates Revision

The market is revising Upward the revenue expectations for MacroGenics, Inc. (MGNX) for FY2025, with the revenue forecasts being adjusted by 53.76% over the past three months. During the same period, the stock price has changed by -6.80%.

Revenue Estimates for FY2025

Revise Upward

+53.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-39.43%

In Past 3 Month

Stock Price

Go Down

-6.80%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

Current: 1.370

Low

2.00

Averages

3.00

High

4.00

Current: 1.370

Low

2.00

Averages

3.00

High

4.00

Barclays

NULL -> Overweight

initiated

2025-09-16

Reason

Barclays

Price Target

2025-09-16

initiated

NULL -> Overweight

Reason

Barclays initiated coverage of MacroGenics with an Overweight rating and $3 price target.

Barclays

Etzer Darout

Overweight

initiated

2025-09-16

Reason

Barclays

Etzer Darout

Price Target

2025-09-16

initiated

Overweight

Reason

Barclays analyst Etzer Darout assumed coverage of MacroGenics with an Overweight rating and $3 price target. The firm believes MGC026 could drive share upside in 2026 due to the shortcomings of the competitor B7H3 antibody drug conjugate programs.

Leerink

Outperform

NULL

downgrade

$8 -> $5

2025-08-15

Reason

Leerink

Price Target

$8 -> $5

2025-08-15

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on MacroGenics to $5 from $8 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 financial results that were largely in line and notably announced the appointment of Eric Risser as President and CEO the day before. Overall, Leerink's thesis on MacroGenics is based on potential royalties and milestone payments related to multiple partnered programs and cash.

B. Riley

Neutral

downgrade

$5 -> $3

2025-05-20

Reason

B. Riley

Price Target

$5 -> $3

2025-05-20

downgrade

Neutral

Reason

B. Riley lowered the firm's price target on MacroGenics to $3 from $5 and keeps a Neutral rating on the shares. The company's key operational updates on a more focused oncology pipeline were noted on its earnings call, with management reaffirming guidance for disclosure of two key trial readouts in 2025, the analyst tells investors in a research note. B. Riley believes the end of selling pressure in the follow-up to the string of vobra duo-related disappointments may be nearing.

Barclays

Peter Lawson

Overweight

downgrade

$8 -> $3

2025-05-14

Reason

Barclays

Peter Lawson

Price Target

$8 -> $3

2025-05-14

downgrade

Overweight

Reason

Barclays analyst Peter Lawson lowered the firm's price target on MacroGenics to $3 from $8 and keeps an Overweight rating on the shares post the earnings report. The firm de-risked the model to reflect the current market environment.

Stifel

Hold

downgrade

$6 -> $5

2025-05-14

Reason

Stifel

Price Target

$6 -> $5

2025-05-14

downgrade

Hold

Reason

Valuation Metrics

The current forward P/E ratio for MacroGenics Inc (MGNX.O) is -0.64, compared to its 5-year average forward P/E of -3.46. For a more detailed relative valuation and DCF analysis to assess MacroGenics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.46

Current PE

-0.64

Overvalued PE

1.73

Undervalued PE

-8.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.70

Undervalued EV/EBITDA

-7.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.01

Current PS

0.00

Overvalued PS

9.30

Undervalued PS

0.72

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MGNX News & Events

Events Timeline

No data

News

9.5

11-13NASDAQ.COM

After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports

9.5

08-14NASDAQ.COM

MacroGenics Revenue Doubles in Q2

9.5

08-13NASDAQ.COM

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

People Also Watch

Frequently Asked Questions

What is MacroGenics Inc (MGNX) stock price today?

The current price of MGNX is 1.37 USD — it has decreased -2.14 % in the last trading day.

What is MacroGenics Inc (MGNX)'s business?

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

What is the price predicton of MGNX Stock?

What is MacroGenics Inc (MGNX)'s revenue for the last quarter?

MacroGenics Inc revenue for the last quarter amounts to 72.84M USD, decreased -34.21 % YoY.

What is MacroGenics Inc (MGNX)'s earnings per share (EPS) for the last quarter?

MacroGenics Inc. EPS for the last quarter amounts to 0.27 USD, decreased -70.00 % YoY.

What changes have occurred in the market's expectations for MacroGenics Inc (MGNX)'s fundamentals?

How many employees does MacroGenics Inc (MGNX). have?

MacroGenics Inc (MGNX) has 341 emplpoyees as of December 16 2025.

What is MacroGenics Inc (MGNX) market cap?

Today MGNX has the market capitalization of 86.66M USD.